Ftse Mib
33.285,03
0,17%
DAX
19.146,17
0,76%
S&P 500
5.954,54
0,63%
NASDAQ
19.021,67
0,29%
Bitcoin
98.128,54
3,99%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acasti Pharma Inc (ACST) Acasti Pharma Inc (ACST) Notizie

ACST

Acasti Pharma (ACST)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACST
DataOraFonteTitoloSimboloCompagnia
28/10/202413:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACSTAcasti Pharma Inc
16/10/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACSTAcasti Pharma Inc
08/10/202413:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACSTAcasti Pharma Inc
08/10/202413:16Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACSTAcasti Pharma Inc
08/10/202413:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ACSTAcasti Pharma Inc
06/09/202422:07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACSTAcasti Pharma Inc
09/08/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACSTAcasti Pharma Inc
07/08/202422:14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACSTAcasti Pharma Inc
31/07/202413:22Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:ACSTAcasti Pharma Inc
11/07/202417:16Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
11/07/202403:10Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACSTAcasti Pharma Inc
10/07/202402:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
10/05/202422:11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
09/05/202401:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
10/10/202313:40Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACSTAcasti Pharma Inc
06/10/202322:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACSTAcasti Pharma Inc
25/08/202322:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACSTAcasti Pharma Inc
10/07/202315:00PR Newswire (US)Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH PatientsNASDAQ:ACSTAcasti Pharma Inc
07/07/202314:00PR Newswire (US)Acasti Pharma Announces 1-for-6 Reverse Stock SplitNASDAQ:ACSTAcasti Pharma Inc
05/07/202315:00PR Newswire (US)Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023NASDAQ:ACSTAcasti Pharma Inc
23/06/202313:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACSTAcasti Pharma Inc
23/06/202313:00PR Newswire (US)Acasti Pharma Reports Fiscal Year 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
22/06/202315:00PR Newswire (US)Acasti Announces Appointment of New Scientific Advisory Board MembersNASDAQ:ACSTAcasti Pharma Inc
26/05/202321:07Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ACSTAcasti Pharma Inc
17/05/202315:00PR Newswire (US)Acasti to Participate in the Lytham Partners Spring 2023 Investor ConferenceNASDAQ:ACSTAcasti Pharma Inc
08/05/202313:00PR Newswire (US)Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025NASDAQ:ACSTAcasti Pharma Inc
05/04/202323:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACSTAcasti Pharma Inc
04/04/202314:01PR Newswire (US)Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDNASDAQ:ACSTAcasti Pharma Inc
04/04/202314:00PR Newswire (US)Acasti Announces Appointment of Prashant Kohli as CEONASDAQ:ACSTAcasti Pharma Inc
30/03/202314:30PR Newswire (US)Acasti Pharma Inc. Announces the Resignation of a DirectorNASDAQ:ACSTAcasti Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACST

La tua Cronologia

LSE
SYNT
Synthomer
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network